The UVA Cancer Center seeks adults aged 60 years or older with newly diagnosed classical Hodgkin Lymphoma for a research study. The purpose of the study is to find out if fitness assessments can help doctors decide what type of treatment is best for cHL patients over the age of 60 with different levels of fitness. This study will also help determine if a study drug, pembrolizumab, is effective as part of the upfront treatment regimen of cHL. Pembrolizumab has been approved for the treatment of relapsed or refractory cHL, but not for the upfront treatment of cHL.
You may be eligible for this study if you are at least 60 years old and if you have newly diagnosed classical Hodgkin lymphoma that has not yet been treated with chemotherapy.
The study involves undergoing fitness assessments, answering questionnaires, and having blood taken for blood tests. The results of the fitness assessments will dictate what treatment you will get. All patients will undergo treatment with a study drug as well as standard drugs approved to treat your disease, but the combinations of these drugs can differ based on the results of the fitness assessment. Additionally, scans will be done to see if the treatments are shrinking your cancer. If your disease grows during or after treatment, the study team might ask you to undergo a biopsy for the research but this is optional. Blood will be drawn 4 times for study purposes. During the active treatment portion of the study, you will come in for up to 20 visits over 18 weeks (about 5 months). Each visit will last about 2 to 7 hours.
Study-related procedures, including but not limited to the biopsies and vaccine, will be provided at no cost.
For more information, please visit Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above - Full Text View - ClinicalTrials.gov